Other

Neuova, LLC

Zor Pharmaceuticals, LLC

Cardiopharma, Inc.

Daniel Tyree Gregory, Jr

Stephan D Glenn

Roy A Stimits

Asher Nathan

Frank Detlev Goj

Wayne L Whittingham

David P Hause

Disclosed is a method of manufacturing a cardiovascular fixed-dose combination pharmaceutical dosage form that includes an anti-hypertensive active agent, a cholesterol-lowering active agent, and optionally, an enteric-coated aspirin or platelet inhibitor. The fixed-dose combination is prepared with at least two granulation solutions that are free of citric acid and enhance the aqueous solubility of the cholesterol-lowering agent in fixed-dose combination. The active agents in the resulting dosage form, which is also free of citric acid, have the same strength and release profiles as the same active agents prepared as a single formulation.

Anti-hypertensive and cholesterol-lowering fixed-dose combination and method of manufacture

A method of making a consumable product containing purified embryonatedova (TSO) preferably includes steps of: storing the TSO in an acidic solution; adding a food preservative to the acidic solution to produce a preservative-acid-solution; forming a mixing solution by raising the pH of the preservative-acidic-solution to match the pH of a food substance by titrating the preservative-acidic-solution with an acid neutralizer so that the pH changes at a rate of not more than 1 pH unit per 24 hours, preferably to a pH not higher than 5.0; and producing the consumable product by combining the mixing solution and the food substance while maintaining the temperature of the consumable product between 1 degree Centigrade and 47 degrees Centigrade.

[object Object]

A method for treating a cancer, by determining a patient to have an ECOG (Eastern Cooperative Oncology Group) score of 0 or 1 and selecting that patient for treatment, and administering to the patient an effective amount of an immunomodulating composition comprising small molecular weight components of less than 3000 daltons, and having the following properties: (i) is extracted from bile of animals; (ii) is capable of stimulating monocytes and/or macrophages; (iii) is capable of modulating tumor necrosis factor production and/or release; (iv) contains no measurable level of IL-1&#x3b1;, IL-1&#x3b2;, TNF, IL-6, IL-8, IL-4, GM-CSF or IFN-&#x3b3;; (v) is not cytotoxic to human peripheral blood mononuclear cells; and (vi) is not an endotoxin. A method of increasing the survival rate of a cancer patient.

Use of immunomodulators for the treatment of cancer

A method for treating a cancer, by determining a patient to have an ECOG (Eastern Cooperative Oncology Group) score of 0 or 1 and selecting that patient for treatment, and administering to the patient an effective amount of an immunomodulating composition comprising small molecular weight components of less than 3000 daltons, and having the following properties: (i) is extracted from bile of animals; (ii) is capable of stimulating monocytes and/or macrophages; (iii) is capable of modulating tumor necrosis factor production and/or release; (iv) contains no measurable level of IL-1&#x3b1;, IL-1&#x3b2;, TNF, IL-6, IL-8, IL-4, GM-CSF or IFN-&#x3b3;; (v) is not cytotoxic to human peripheral blood mononuclear cells; and (vi) is not an endotoxin.

Growing community of inventors

Hampstead, NC, United States of America

Daniel Tyree Gregory, Jr